Schisandra

Metadata

Approved Indications

Commission E (Germany)

• No monograph exists. Schisandra was not part of the German phytotherapy tradition evaluated during the Commission E period (1978-1994). The herb’s primary traditional use was in Chinese and Russian/Soviet medicine.

ESCOP

• No monograph. Not within the scope of ESCOP assessment to date.

EMA/HMPC

• Community herbal monograph adopted (9 January 2017): EMA/HMPC/681100/2013
• Category: Traditional use registration
• Approved indication: “Traditional herbal medicinal product used in conditions of asthenia such as fatigue and weakness”
• Herbal preparations covered: Comminuted herbal substance for herbal tea; dry extract (DER 15-25:1), extraction solvent ethanol 70% (V/V); dry extract (DER 2.5-6:1), extraction solvent ethanol 40% (V/V)
• Age: Adults only (18+)
• Duration: If symptoms persist beyond 2 weeks during use, a physician should be consulted
• Assessment basis: Traditional use classification — at least 30 years of medicinal use, including at least 15 years within the EU, with plausible efficacy based on traditional use experience

HMPC Assessment Notes

• The HMPC assessment report (EMA/HMPC/680381/2013) reviewed the extensive body of preclinical and clinical evidence but concluded that the evidence from clinical trials alone was insufficient for “well-established use” classification.
• The committee noted the large body of Russian and Chinese pharmacological research but expressed concerns about the methodological quality, accessibility, and reproducibility of the Soviet-era studies.
• Notable: Schisandra is one of the adaptogens recognized by the HMPC, alongside Rhodiola rosea and Eleutherococcus senticosus.

Chinese Pharmacopoeia

• Listed: Yes. Wu Wei Zi (Schisandrae Chinensis Fructus) is an official drug in the Chinese Pharmacopoeia (2020 edition).
• Traditional indications: Astringing and replenishing qi, nourishing kidney and calming the heart; used for chronic cough and dyspnea, spontaneous sweating, night sweats, seminal emission, chronic diarrhea, insomnia, palpitations, and excessive thirst.
• Quality standard: Total schisandrins content not less than 0.4% (HPLC).

Russian Pharmacopoeia

• Listed: Yes. Limonnik (Schisandra chinensis) has been an official drug in Soviet and Russian pharmacopoeias since 1961.
• Traditional indications: Asthenia, physical and mental fatigue, convalescence, neurasthenia.
• Historical significance: Schisandra was one of the key plants studied in the USSR adaptogen research program led by Nikolai Lazarev, Israel Brekhman, and later Alexander Panossian. Soviet military and industrial research explored its use for enhancing physical endurance and cognitive performance under extreme conditions (Arctic expeditions, military operations, industrial labor).

United States

• Dietary supplement: Available under DSHEA. Not a USP-monographed supplement.
• Not FDA GRAS: No GRAS determination for schisandra.

Agreement/Disagreement

• Regulatory gap: Schisandra has a single European regulatory endorsement (EMA/HMPC traditional use) but no Commission E or ESCOP monographs, reflecting its origin outside the traditional European herbal pharmacopoeia.
• Cross-cultural consistency: The TCM, Russian, and EMA indications converge on fatigue and weakness/asthenia, despite arising from entirely different medical traditions.
• Conservative classification: Like Rhodiola, the HMPC classified Schisandra under “traditional use” rather than “well-established use,” despite the large volume of research.

Conditions Treated

Primary (Moderate Evidence)

• Physical and mental stress adaptation (adaptogenic) — EMA/HMPC-approved traditional indication; supported by Panossian systematic reviews and Soviet-era research demonstrating enhanced work capacity and stress tolerance.
• Hepatoprotection — Schisandrin B and related lignans reduce elevated liver enzymes (ALT, AST) in toxic and viral hepatitis; widely used in China for drug-induced liver injury; mechanism involves glutathione system enhancement and anti-fibrotic activity.

Secondary (Preliminary Evidence)

• Cognitive performance under stress — ADAPT-232 combination formula studies (Panossian et al. 2009, Aslanyan et al. 2010) show improved attention, speed, and accuracy during cognitive tasks under stress and fatigue conditions.
• Exercise endurance and physical performance — Soviet-era studies in athletes and military personnel reported enhanced endurance; modern studies are limited but suggestive.

Emerging/Preclinical

• Anti-inflammatory — Schisandrin B inhibits NF-kB pathway and reduces pro-inflammatory cytokines in animal models.
• Neuroprotection — Schisandrin B and schisandrin demonstrate neuroprotective effects in models of Alzheimer’s disease, Parkinson’s disease, and ischemic brain injury through mitochondrial protection and antioxidant activity.
• Anti-aging and longevity — Preclinical evidence of mitochondrial glutathione enhancement, telomere protection, and sirtuin activation; no clinical evidence.

Mechanism of Action

Primary Mechanisms

1. Hepatoprotection via glutathione system enhancement: Schisandrin B is the primary hepatoprotective lignan. It enhances the hepatic glutathione antioxidant system by inducing glutathione reductase and glutathione S-transferase activity, increasing reduced glutathione (GSH) levels in hepatocytes. This protects against oxidative liver damage from toxins (carbon tetrachloride, acetaminophen, alcohol) and viral hepatitis. Additionally, schisandrin B demonstrates anti-fibrotic activity by inhibiting hepatic stellate cell activation and reducing collagen deposition.

2. Adaptogenic effects via HPA axis and cortisol modulation: Schisandra lignans modulate the hypothalamic-pituitary-adrenal (HPA) axis, normalizing cortisol levels under stress conditions. Unlike simple cortisol suppression, adaptogens like schisandra are proposed to calibrate the stress response — preventing both excessive cortisol elevation and stress-induced cortisol depletion. Panossian and Wikman (2010) describe this as maintaining cortisol within a “zone of protection.”

3. HSP70 induction (heat shock protein — cellular stress protection): Schisandrin B and related lignans induce the expression of heat shock protein 70 (HSP70/Hsp72), a molecular chaperone that protects cellular proteins from stress-induced damage (heat, oxidative stress, toxins). This is considered a key molecular mechanism underlying the adaptogenic “non-specific stress resistance” effect. Panossian et al. (2012) identified HSP70 induction as a common molecular target of clinically validated adaptogens.

Secondary Mechanisms

4. Antioxidant lignan activity: The dibenzocyclooctadiene lignans act as direct free radical scavengers and inhibit lipid peroxidation. Schisandrin B is a particularly potent antioxidant in both in vitro and in vivo models, with activity in mitochondrial membranes where it protects against oxidative phosphorylation uncoupling.

5. CNS effects via GABA-A and glutamate modulation: Schisandrin and gomisin A demonstrate GABAergic activity, acting as positive modulators of GABA-A receptors, contributing to anxiolytic and mild sedative effects. Concurrently, schisandrin B modulates glutamatergic neurotransmission and inhibits excessive NMDA receptor activation, providing neuroprotective and cognitive-enhancing effects.

6. Nitric oxide modulation: Schisandra lignans modulate nitric oxide (NO) production, with context-dependent effects: inhibiting excessive NO production under inflammatory conditions (via iNOS inhibition) while supporting endothelial NO synthase (eNOS) for vascular function.

Pharmacokinetic Interactions

7. CYP3A4 inhibition and P-glycoprotein modulation: Schisandrin, schisandrin B, and gomisin A are clinically significant inhibitors of cytochrome P450 3A4 (CYP3A4) and modulators of P-glycoprotein (P-gp) efflux transporter. This dual inhibition increases the bioavailability and reduces the clearance of co-administered drugs that are CYP3A4 substrates or P-gp substrates. This property is therapeutically exploited in Chinese medicine (pairing schisandra with other drugs to enhance their bioavailability) but represents a significant drug interaction risk.

Clinical Evidence Summary

Clinical evidence for standalone Schisandra chinensis is limited by the predominance of Soviet-era research (often difficult to access, verify, or replicate by modern standards) and the use of combination adaptogen formulas in modern trials. No large standalone RCTs meeting current CONSORT standards have been published.

Systematic Reviews and Meta-Analyses

Combination Formula Trials (ADAPT-232 and Chisan)

Hepatoprotection Studies

Soviet-Era Research Legacy

• Extensive studies conducted from the 1950s-1980s under the USSR Academy of Sciences adaptogen research program (Brekhman, Dardymov, and later Panossian).
• Studies documented enhanced physical endurance, cognitive function under stress, and stress adaptation in military personnel, athletes, factory workers, and Arctic expedition members.
• Limitations: Much of this research was published in Russian-language journals that are difficult to access; study designs often do not meet modern Western standards (lack of randomization, blinding, or intention-to-treat analysis); sample sizes were typically small; some studies remain untranslated and unverifiable.
• Significance: Despite methodological limitations, the consistency and volume of Soviet-era findings across multiple populations and endpoints provide plausibility support for the adaptogenic concept as applied to schisandra.

Evidence Limitations

• No large (n>100) standalone Schisandra chinensis RCTs meeting current CONSORT reporting standards.
• ADAPT-232 and Chisan studies cannot isolate the contribution of schisandra from other formula components (Rhodiola, Eleuthero).
• Hepatoprotection evidence is strongest from Chinese clinical studies, many of which are open-label or lack rigorous blinding.
• Soviet-era studies are foundational but do not meet contemporary evidence standards.
• Dose-response relationships are poorly characterized in human studies.

Safety Profile

General Assessment

Schisandra chinensis fruit is generally well-tolerated with a long history of safe use in both TCM (>1500 years) and Russian medicine (>60 years of systematic use). The EMA/HMPC assessment (2017) concluded that safety data is adequate for traditional use registration.

Contraindications

• Pregnancy: Contraindicated. Schisandra has documented uterotonic activity in animal studies and traditional TCM sources advise against use during pregnancy. No human safety data in pregnancy.
• Lactation: Insufficient data. Avoid until safety is established.
• Epilepsy and seizure disorders: Use with caution. Schisandrin modulates GABAergic and glutamatergic neurotransmission; effects on seizure threshold are uncertain and may be biphasic.
• Acute hepatitis: While schisandra is hepatoprotective at normal doses, use during acute hepatic inflammation should be supervised by a physician.

Drug Interactions

• CYP3A4 substrates: Clinically significant interaction. Schisandrin and schisandrin B are potent CYP3A4 inhibitors. Co-administration with CYP3A4-metabolized drugs (tacrolimus, cyclosporine, midazolam, statins, calcium channel blockers, HIV protease inhibitors) may substantially increase their plasma levels. Case reports: Elevated tacrolimus blood levels requiring dose adjustment have been reported in transplant patients taking schisandra concurrently (Xin et al. 2007). Similar interactions reported with cyclosporine.
• P-glycoprotein substrates: Schisandra lignans inhibit P-glycoprotein efflux, potentially increasing the bioavailability of P-gp substrate drugs (digoxin, dabigatran, certain chemotherapy agents). Pharmacokinetic interaction studies in healthy volunteers confirmed increased bioavailability of the P-gp probe substrate talinolol (Fan et al. 2009).
• Warfarin and anticoagulants: Theoretical interaction via CYP modulation and possible effects on coagulation pathways. Monitor INR closely if co-administered.
• Other CYP substrates: In vitro evidence of inhibition of CYP2C9 and CYP1A2, though clinical significance is less well established than CYP3A4 inhibition.

Side Effects (at recommended doses)

• Common: Mild gastrointestinal effects including heartburn, acid reflux, and epigastric discomfort (attributable to the acidic nature of the fruit — schisandra is predominantly sour/acidic).
• Uncommon: Allergic skin reactions, decreased appetite.
• Rare: Paradoxical hepatotoxicity has been reported at very high doses or with concentrated extracts, particularly schisantherin A-rich preparations. This is a dose-dependent phenomenon: hepatoprotective at normal doses, potentially hepatotoxic at supraphysiological doses.

Toxicology

• Acute oral LD50 in mice: approximately 3.6 g/kg extract (relatively low acute toxicity).
• No evidence of genotoxicity or mutagenicity in standard Ames test and micronucleus assays.
• The EMA/HMPC assessment noted that the available toxicological data supports safe use at recommended traditional doses.

Clinical Dosage

Dried Fruit (Herbal Tea / Decoction)

• Standard dose: 1.5-6 g/day of dried fruit
• TCM decoction: 2-6 g daily in divided doses
• EMA/HMPC dosing (herbal tea): 1.5-6 g of comminuted herbal substance in 150 mL boiling water, 1-3 times daily

Standardized Extract

• Standard dose: 200-500 mg/day of extract standardized to 2-9% total schisandrins
• EMA/HMPC dosing (dry extract): 64-128 mg extract (DER 15-25:1, ethanol 70%) one to three times daily; OR 113-340 mg extract (DER 2.5-6:1, ethanol 40%) one to three times daily

Tincture

• Standard dose: 2-4 mL of tincture (1:5, ethanol 70%) twice daily
• Russian pharmacopoeia tradition: 20-30 drops of tincture, 2-3 times daily

Combination Formulas

• ADAPT-232: Proprietary combination of Schisandra + Rhodiola + Eleuthero; clinical studies used manufacturer-specified doses
• Note: Combination formula dosing does not provide guidance for standalone schisandra dosing

Duration of Use

• EMA/HMPC recommends consultation with a physician if symptoms persist beyond 2 weeks
• Traditional use in TCM and Russian medicine supports longer-term use (weeks to months) at standard doses

Sources

• EMA/HMPC. Community herbal monograph on Schisandra chinensis (Turcz.) Baill., fructus. EMA/HMPC/681100/2013. January 2017
• EMA/HMPC. Assessment report on Schisandra chinensis (Turcz.) Baill., fructus. EMA/HMPC/680381/2013. January 2017
• Panossian A, Wikman G. Evidence-based efficacy of adaptogens in fatigue, and molecular mechanisms related to their stress-protective activity. Curr Clin Pharmacol. 2009;4(3):198-219
• Panossian A, Wikman G. Pharmacology of Schisandra chinensis Bail.: an overview of Russian research and uses in medicine. J Ethnopharmacol. 2008;118(2):183-212
• Panossian AG, Efferth T, Shikov AN, et al. Evolution of the adaptogenic concept from traditional use to medical systems: pharmacology of stress- and aging-related diseases. Med Res Rev. 2021;41(1):364-407
• Panossian A, Hambardzumyan M, Hovhannisyan A, Wikman G. The adaptogens rhodiola and schizandra modify the response to immobilization stress in rabbits by suppressing the increase of phosphorylated stress-activated protein kinase, nitric oxide and cortisol. Drug Target Insights. 2007;2:39-54
• Panossian A, Wikman G, Kaur P, Asea A. Adaptogens exert a stress-protective effect by modulation of expression of molecular chaperones. Phytomedicine. 2009;16(6-7):617-622
• Panossian A, Wikman G, Kaur P, Asea A. Adaptogens stimulate nociceptive and HSP72 expression and release in neuroglia cells. Front Neurosci. 2012;6:6
• Aslanyan G, Amroyan E, Gabrielyan E, et al. Double-blind, placebo-controlled, randomised study of single dose effects of ADAPT-232 on cognitive functions in the phase of intensive mental work. Phytomedicine. 2010;17(7):494-499
• Nowak A, Zaklos-Szyda M, Blasiak J, Nowak A, Zhang Z, Zhang B. Potential of Schisandra chinensis (Turcz.) Baill. in human health and nutrition: a review of current knowledge and therapeutic perspectives. Nutrients. 2019;11(2):333
• Opletal L, Sovova H, Bartlova M. Dibenzo[a,c]cyclooctadiene lignans of the genus Schisandra: importance, isolation and determination. J Chromatogr B Analyt Technol Biomed Life Sci. 2004;812(1-2):357-371
• Ip SP, Mak DH, Li PC, Poon MK, Ko KM. Effect of a lignan-enriched fructus schisandrae extract on hepatic glutathione status in rats: protection against carbon tetrachloride toxicity. Planta Med. 1996;62(4):325-328
• Ip SP, Poon MK, Che CT, et al. Schisandrin B protects against carbon tetrachloride toxicity by enhancing the mitochondrial glutathione redox status in mouse liver. Free Radic Biol Med. 2000;29(2):172-179
• Xin HW, Wu XC, Li Q, Yu AR, Zhong MY, Liu YY. The effects of berberine on the pharmacokinetics of cyclosporin A in healthy volunteers. Methods Find Exp Clin Pharmacol. 2006;28(1):25-29
• Fan L, Mao XQ, Tao GY, et al. Effect of Schisandra chinensis extract and Ginkgo biloba extract on the pharmacokinetics of talinolol in healthy volunteers. Xenobiotica. 2009;39(3):249-254
• Chiu PY, Mak DH, Poon MK, Ko KM. In vivo antioxidant action of a lignan-enriched extract of Schisandra fruit and an anthraquinone-containing extract of Polygonum root in comparison with schisandrin B and emodin. Planta Med. 2002;68(11):951-956
• Chinese Pharmacopoeia Commission. Pharmacopoeia of the People’s Republic of China. Vol 1. 2020 Edition
• State Pharmacopoeia of the USSR. 11th Edition. Moscow: Meditsina, 1990

Connections

• Compare with other adaptogens with EMA/HMPC monographs: rhodiola (the most formally recognized adaptogen in European phytotherapy), eleuthero (Commission E, ESCOP, and EMA recognition)
• Schisandra is unique in bridging TCM and Russian adaptogen traditions — rhodiola originates from Scandinavian/Russian tradition, while eleuthero is primarily from the Russian research program
• Hepatoprotective comparison with milk thistle (silymarin) — both demonstrate liver enzyme normalization, but through different mechanisms: silymarin via membrane stabilization and anti-fibrotic effects, schisandrin B via glutathione system enhancement
• Component of ADAPT-232 combination formula alongside rhodiola and eleuthero; clinical evidence for this combination may not reflect standalone schisandra effects
• The CYP3A4 and P-glycoprotein inhibition profile distinguishes schisandra from most other adaptogens and requires careful attention to drug interactions, similar to the interaction profile of St. John’s wort (which is an inducer rather than inhibitor)
• Compare adaptogenic mechanisms with ashwagandha (withanolide-mediated, also with cortisol modulation) and rhodiola (rosavin/salidroside-mediated, HPA axis modulation)